Bavisant
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Bavisant (INN, USAN; developmental code names BEN-2001 and JNJ-31001074) is a histamine H3 receptor receptor antagonist which was under development for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD) but was never marketed.[1][4][2][5] It is taken orally.[1][5]
- None
| |
| Clinical data | |
|---|---|
| Other names | BEN-2001; BEN2001; JNJ-1074; JNJ1074; JNJ-31001074; JNJ31001074 |
| Routes of administration | Oral[1] |
| Drug class | Histamine H3 receptor receptor antagonist; Wakefulness-promoting agent |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 14–22 hours[2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H27N3O2 |
| Molar mass | 329.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug is potent and highly selective for the histamine H3 receptor (Ki = 5.4 nM).[2][5][3] Bavisant produces wakefulness-promoting effects in animals and humans, but can also cause insomnia.[2][5] Its elimination half-life is 14 to 22 hours while its effective half-life is 13 to 20 hours.[2][3]
Bavisant was under development by BenevolentAI and Johnson & Johnson.[1] It reached phase 2 clinical trials for both narcolepsy and ADHD prior to the discontinuation of its development in 2022.[1] The drug was not effective for the treatment of ADHD in a large clinical trial.[2][5] Besides the preceding indications, it was also studied for the treatment of alcoholism.[2][4] In 2026, bavisant was identified as a potential therapeutic agent for the treatment of multiple sclerosis.[6]